{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:40:56Z","timestamp":1763037656236,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jneuroim.2021.577726","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T01:53:25Z","timestamp":1632880405000},"page":"577726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ixekizumab exposure associated with myelitis: A case report and a literature review"],"prefix":"10.1016","volume":"361","author":[{"given":"Marina","family":"Romozzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bellavia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Luigetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Masullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577726_bb0005","first-page":"232986","article-title":"Bilateral optic neuritis associated with the use of infliximab","volume":"2011","author":"Aasly","year":"2011","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"10.1016\/j.jneuroim.2021.577726_bb0010","first-page":"671935","article-title":"Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature","volume":"2013","author":"Andreadou","year":"2013","journal-title":"Case Rep. Neurol. Med."},{"issue":"5","key":"10.1016\/j.jneuroim.2021.577726_bb0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ced.13412","article-title":"Demyelination during anti-tumour necrosis factor therapy for psoriasis","volume":"43","author":"Boggs","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2021.577726_bb0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","article-title":"Adalimumab-associated optic neuritis","volume":"244","author":"Chung","year":"2006","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neurol.2011.06.005","article-title":"Neurological adverse events under anti-TNF alpha therapy","volume":"168","author":"Cohen","year":"2012","journal-title":"Rev. Neurol. (Paris)"},{"issue":"8","key":"10.1016\/j.jneuroim.2021.577726_bb0030","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s00415-021-10460-6","article-title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","volume":"268","author":"Cortese","year":"2021","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2021.577726_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.jneuroim.2021.577726_bb0040","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.semarthrit.2011.05.003","article-title":"Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review","volume":"41","author":"Cruz Fern\u00e1ndez-Espartero","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.jneuroim.2021.577726_bb0045","first-page":"1469","article-title":"Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies","volume":"35","author":"Davis","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2021.577726_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","article-title":"A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions","volume":"31","author":"Diebold","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2021.577726_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419895155","article-title":"PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-\u03b1 therapy-associated demyelinating disorders","volume":"13","author":"Engel","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0060","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jaad.2013.08.047","article-title":"Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis","volume":"70","author":"Escalas","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jneuroim.2021.577726_bb0065","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-2-1","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.55563\/clinexprheumatol\/rl668e","article-title":"Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary","volume":"39","author":"Fonti","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2021.577726_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000109576","article-title":"Multiple sclerosis onset during etanercept treatment","volume":"59","author":"Gomez-Gallego","year":"2008","journal-title":"Eur. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2021.577726_bb0080","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2021.577726_bb0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cei.12219","article-title":"Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation","volume":"175","author":"Hu","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.jneuroim.2021.577726_bb0095","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jneuroim.2021.577726_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","volume":"72","author":"Kimball","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.jneuroim.2021.577726_bb0110","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jneuroim.2021.577726_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"issue":"9625","key":"10.1016\/j.jneuroim.2021.577726_bb0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2021.577726_bb0125","doi-asserted-by":"crossref","first-page":"577525","DOI":"10.1016\/j.jneuroim.2021.577525","article-title":"Defining the disease course of TNF\u03b1 blockers-associated multiple sclerosis","volume":"353","author":"Lucchini","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/09546634.2012.660520","article-title":"Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature","volume":"24","author":"Mahil","year":"2013","journal-title":"J. Dermatolog. Treat"},{"issue":"9","key":"10.1016\/j.jneuroim.2021.577726_bb0135","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00415-016-8238-5","article-title":"Extensive and severe CNS demyelination associated with golimumab therapy","volume":"263","author":"Maillart","year":"2016","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jneuroim.2021.577726_bb0140","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1111\/ijd.14902","article-title":"Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?","volume":"59","author":"Megna","year":"2020","journal-title":"Int. J. Dermatol."},{"issue":"12","key":"10.1016\/j.jneuroim.2021.577726_bb0145","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jneuroim.2021.577726_bb0150","first-page":"567","article-title":"Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis: first case in Italy?","volume":"153","author":"Napolitano","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.jneuroim.2021.577726_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jneuroim.2021.577726_bb0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jneuroim.2021.577726_bb0165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.jneuroim.2021.577726_bb0170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00415-009-5361-6","article-title":"Acute transverse myelitis in psoriatic arthritis","volume":"257","author":"Rath","year":"2010","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2021.577726_bb0175","first-page":"1457","article-title":"Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab","volume":"33","author":"Ruiz-Jimeno","year":"2006","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.jneuroim.2021.577726_bb0180","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000485499","article-title":"Infliximab-associated chronic inflammatory central nervous system disease and peroneal nerve injury in a psoriatic patient refractory to treatment: case report with 10-year follow-up","volume":"10","author":"Signore","year":"2018","journal-title":"Case Rep. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577726_bb0190","first-page":"81","article-title":"A narrative review of psoriasis and multiple sclerosis: links and risks","volume":"9","author":"Silfvast-Kaiser","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"12","key":"10.1016\/j.jneuroim.2021.577726_bb0195","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2021.577726_bb0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","article-title":"Etanercept and demyelinating disease in a patient with psoriasis","volume":"54","author":"Sukal","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.jneuroim.2021.577726_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.jneuroim.2021.577726_bb0210","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"issue":"Suppl. 6","key":"10.1016\/j.jneuroim.2021.577726_bb0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00415-008-6020-z","article-title":"Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy","volume":"255","author":"Winkelmann","year":"2008","journal-title":"J. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:39:58Z","timestamp":1759048798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":43,"alternative-id":["S0165572821002538"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577726","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixekizumab exposure associated with myelitis: A case report and a literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577726"}}